1. ADACHI, M., TAKI, T., KONISHI, T., HUANG, C.I., HIGASHIYAMA, M., MIYAKE, M., Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression, J Clin Oncol, 16 (4), 1397-1406, 1998.
2. AMADO, R.G., CHEN, I.S.Y., Lentiviral vectors-the promise of gene therapy within reach?, Science, 285, 674-676, 1999.
3. ASOSINGH, K., DE RAEVE, H., MENU, E., et al., Angiogenic switch during 5T2MM murine myeloma tumorgenesis: role of CD45 heterogenicity, Blood, 103, 3131-3137, 2004.
4. BAKKUS, M.H.C., HEIRMAN, C., VAN RIET, I., VAN CAMP, B., THIELEMANS, K., Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation, Blood, 80, 2326-2335, 1992.
5. BAKKUS, M.H.C., ASOSINGH, K., VANDERKERKEN, K., THIELEMANS, K., HAGEMEIJER, A., DE RAEVE, H., VAN CAMP, B., Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour, Leukemia, 15, 1127-1132, 2001.
6. BARRENA, S., ALMEIDA, J., YUNTA, M., LOPEZ, A., FERNANDEZ-MOSTEIRIN, N., GIRALT, M., et al., Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation, Leukemia, 19 (8), 1376-83, 2005.
7. BAYLIN, S.B., HERMAN, J.G., DNA hypermethylation in tumorgenesis: Epigenetics joins genetics, Trends Genet, 16, 168-174, 2000.
8. BERDITCHEVSKI, F., Complexes of tetraspanins with integrins: more than meets the eye, J. Cell Sci, 114, 4143-4151, 2001.
9. BERGSAGEL, P.L., KEUHL, W.M., Chromosome translocations in multiple myeloma, Oncogene, 20, 5611-5622, 2001.
10. BHALLA, K.N., Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies, Journal of Clinical Oncology, 23 (17), 3971-3993, 2005.
11. BIRD, A., DNA methylation patterns and epigenetic memory, Genes Dev, 16, 6-21, 2002.
12. BOUCHEIX., C., et al., Molecular cloning of the CD9 antigen. A new family of cell surface proteins, J Biol Chem, 266, 117-122, 1991.
13. BOUCHEIX, C., DUC, G.H., JASMIN, C., RUBINSTEIN, E., Tetraspanins and malignancy, Expert Rev Mol Med, 2001, 1-17, 2001.
14. BOUCHEIX, C., RUBINSTEIN, E., Tetraspanins, Cell Mol Life Sci, 58 (9), 1189-1205, 2001.
15. BUTCHER, E.C., PICKER, L.J., Lymphocyte homing and homeostasis, Science, 272, 60-66, 1996.
16. CALIGARIS-CAPPIO, F., BERGUI, L., GREGORETTI, M.G., et al., Role of the bone marrow stromal cells in the growth of human multiple myeloma, Blood, 77, 2688-2693, 1991.
17. CATLEY, L., WEISBERG, E., TAI, Y.T., ATADJA, P., REMISZEWSKI, S., HIDESHIMA, T., et al., NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity againts multiple myeloma, Blood, 102 (7), 2615-2622, 2003.
18. CATLEY, L., WEISBERG, E., KIZILTEPE, T., TAI, Y.T., HIDESHIMA, T., NERI, P., et al., Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells, Blood, 108 (10), 3441-3449, 2006.
19. CHRISTMAN, J.K., 5-Aza-cytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic study and their implications for cancer therapy, Oncogene, 21 (35), 5483-5495, 2002.
20. CHIM, C.S., KWONG, Y.L., FUNG, T.K., LIANG, R., Methylation profiling in multiple myeloma, Leuk Res, 28 (4), 379-385, 2004.
21. CLARK, D.P., Molecular Biology, Understanding the genetic revolution, Elsevier, 2005.
22. DALTON, W.S., BERGSAGEL, L., KEUHL, W.M., ANDERSON, K.C., HAROUSSEAU, J.L., Multiple Myeloma, Hematology Am soc Hematol Educ Prog, 157-177, 2001.
23. DAMIANO, S., CRESS, A.E., HAZLEHURST, L.A., SHTIL, A.A., DALTON, W.S., Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines, Blood, 93, 1658-1667, 1999.
24. DAMIANO, S., DALTON, W.S., Integrin-mediated drug resistance in multiple myeloma, Leuk Lymphoma, 38, 71-81, 2000.
25. DE BRUYNE, E., MENU, E., VAN VALCKENBORG, E., DE RAEVE, H., VAN CAMP, B., VAN RIET, I., VANDERKERKEN, K., Myeloma cells and their interactions with the bone marrow endothelial cells, Current Immunolgy Reviews, 3, 41-55, 2007.
26. DEBYSER, Z., Viral vectors for gene therapy, Rega Institute for Medical Research KUL, 2000.
27. DE RAEVE, H., VAN MARCK, E., VAN CAMP, B., VANDERKERKEN, K., Angiogenesis and the role of bone marrow endothelial cells in the haematological malignancies, Histol Histopathol, 19, 935-950, 2004.
28. DEVITRA, J. V.T., HELLMAN, S., ROSENBERG, S.A., et al., Cancer: Principles and Practice of Oncology, 5de editie, 1997.
29. DRUCKER, L., TOHAMI, T., TARTAKOVER-MATALON, S., ZISMANOV, V., SHAPIRO, H., RADNAY, J., et al., Promotor hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines, Carcinogenesis, 27 (2), 197-204, 2006.
30. DU, H.L., Qi, Y., SHI, Y.J., BU, D.F., WU, S.L., Apoptosis and re-expression of p-16 gene in the myeloma cell line U266 induced by synergy of histone deacetylase inhibitor and demethylating agent, Ai Zheng, 21 (10), 1057-1061, 2002.
31. EHRLICH, M., DNA methylation in cancer: Too much, but also too little, Oncogene, 21, 5400-5413, 2002.
32. ESTELLER, M., HERMAN, J.G., Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours, J Pathol, 196, 1-7, 2002.
33. FEINBERG, A.P., TYCKO, B., The history of cancer epigenetics, Nat Rev Cancer, 4, 143-153, 2004.
34. FELSENFELD, G., GROUDINE, M., Controlling the double helix, Nature, 421 (6921), 448-453, 2003.
35. FERLIN, M., NORAZ, N., HERTOGH, C., BROCHIER, J., TAYLOR, N., KLEIN, B., Insulin-like growth factor I induces the survival and proliferation of myeloma cells through an interleukin-6-independant transduction pathway, Br. J., Haematol., 111, 626-634, 2000.
36. FERGUSON, A.T., VERTINO, P.M., SPITZNER, J.R., BAYLIN, S.B., MULLER, M.T., DAVIDSON, N.E., Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2’deoxycytidine-induced cytotoxicity in human breast cancer cells, J Biol Chem, 272 (51), 32260-32266, 1997.
37. FINNIN, M.S., DONIGIAN, J.R., COHEN, A., RICHON, V.M., RIFKIND, R.A., MARKS, P.S., BRESLOW, R., PAVLETICH, N.P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors, Nature, 401, 188-193, 1999.
38. FUKS, F., DNA methylation and histone modifications:teaming up to silence genes, Curr Opin Genet Dev, 15 (5), 490-495, 2005.
39. GABBARA, S., BHAGWAT, A.S., The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor, Biochem J., 307 (1), 87-92, 1995.
40. GALM, O., YOSHIKAWA, H., ESTELLER, M., OSIEKA, R., HERMAN, J.G., SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma, Blood, 101 (7), 2784-2788, 2003.
41. GALM, O., WILOP, S., REICHELT, J., JOST, E., GEHBAUER, G., HERMAN, J.G., OSIEKA, R., DNA methylation changes in multiple myeloma, Leukemia, 18, 1687-1692, 2004.
42. GALM, O., HERMAN, J.G., BAYLIN, S.B., The fundamental role of epigenetics in hematopoietic malignancies, Blood Reviews, 20, 1-13, 2006.
43. GARDINER-GARDEN, M., FROMMER, M., CpG islands in vertebrate genomes, J Mol Biol, 196, 261-282, 1987.
44. GEORGII-HEMMING, P., WIKLUND, H.J., LJUNGGREN, O., NILSSON, K., Insulin-like growth factor I is a growth and survival factor for human multiple myeloma cell lines, Blood, 88, 2250-2258, 1996.
45. GIULIANI, N., COLLA, S., RIZOLLI, V., Angiogenetic switch in multiple myeloma, Haematology, 9, 377-381, 2004.
46. GOFFIN, J., EISENHAUER, E., DNA methyltransferase inhibitors-state of the art, Ann Oncol, 13 (11), 1699-1716, 2002.
47. HAGGARTY, S.J., KOELLER, K.M., WONG, J.C., GROZINGER, C.M., SCHREIBER, S.L., Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation, Proc Natl Acad Sci USA, 100, 4389-4394, 2003.
48. HALLEK, M., BERGSAGEL, P.L., ANDERSON, K.C., Multiple myeloma: increasing evidence for a multisstep transformation process, Blood, 91, 3-21, 1998.
49. HEMLER, M.E., Integrin associated proteins, Curr Opin Cell Biol, 10 (5), 578-585, 1998.
50. HEMLER, M.E., Specific tetraspanin functions, J Cell Biol, 155 (7), 1103-1107, 2001.
51. HERMAN, J.G., BAYLIN, S.B., Gene silencing in cancer association with promotor hypermethylation, N Engl J Med, 349, 2042-2054, 2003.
52. HIDESHIMA, T., ANDERSON, K.C., Molecular mechanisms of novel therapeutic approaches for multiple myeloma, Nt Rev Cancer, 2, 927-937, 2002.
53. HOLLIDAY, R., GRIGG, G.W., DNA methylation and mutation, Mutat Res, 285, 61-67, 1993.
54. HOULE, C.D., DING, X.Y., FOLEY, J.F., AFSHARI, C.A., BARRETT, J.C., DAVIS, B.J., Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression, Gynaecol Oncol, 86 (1), 69-78, 2002.
55. ISSA, J.P., CpG island methylator phenotype in cancer, Nat Rev Cancer, 4, 988-993, 2004.
56. JANEWAY, C.A., TRAVERS, P., WALPORT, M., SHLOMCHIK, M.J., Immunobiology the immune system in health and disease, Churchill livingstone, Garland Science, Taylor and Frances Group, zesde editie, 2005.
57. JONES, P.A., TAYLOR, S.M., Cellular differentiation, cytidine analogs and DNA methylation, Cell., 20 (1), 85-93, 1980.
58. JONES, P.A., The DNA methylation paradox, Trends Genet, 15, 34-37, 1999.
59. JONES, P.A., BAYLIN, S.B., The fundamental role of epigenetic events in cancer, Nat Rev Genet, 3, 415-428, 2002.
60. JUTTERMANN, R., LI, E., JAENISCH, R., Toxicity of 5-aza-2’-deoxycytidine to mammalian cells is mediated by covalent trapping of DNA methyltransferase rather than DNA methylation, Proc Natl Acad Sci USA, 91 (25), 11797-11801, 1994.
61. KHAN, S.B., MAUDUDI, T., BARTON, K., AYERS, J., ALKAN, S., Analysis of histone deacetylase inhibitor depsipeptide (FR901228), effect on multiple myeloma, Br J Haematol, 125 (2), 156-161, 2004.
62. KEUHL, W.M., BERGSAGEL, P.L., Multiple myeloma: evolving genetic events and host interactions, Nat Rev Cancer, 2, 175-187, 2002.
63. KLIMATCHEVA, E., ROSENBLATT, J.D., PLANELLES, V., Lentiviral vectors and gene therapy, Frontiers in Bioscience, 4, 481-496, 1999.
64. KUBY, J., KINDT, T.J., GOLDSBY, R.A., OSBORNE, B.A., Immunology, Freeman, zesde editie, 2007.
65. LANDOWSKI, T.H., OLASHAW, N.E., AGRAWAL, D., DALTON, W.S., Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells, Oncogene, 22 (16), 2417-2421, 2003.
66. LOKHORST, H.M., LAMME, T., DE SMET, M., et al., Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures, Blood, 84, 2269-2277, 1994.
67. MAECKER, H.T., TODD, S.C., LEVY, S., The tetraspanin superfamily: molecular facilitators, FASEB J., 11 (9), 428-442, 1997.
68. MAISO, P., CARVAJAL-VERGARA, X., OCIO, E.M., LOPEZ-PEREZ, R., MATEO, G., GUTIERREZ, N., et al., The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance, Cancer Res, 66 (11), 5781-5789, 2006.
69. MARTIN, F., ROTH, D.M., JANS, D.A., POUTON, C.W., PARTRIDGE, L.J., MONK, P.N., et al., Tetraspanins in viral infections: a fudamental role in viral biology?, J Virol, 79 (17), 10839-10851, 2005.
70. MATEOS, M.V., GARCIA-SANZ, R., LOPEZ-PEREZ, R., MORO, M.J., OCIO, E., HERNANDEZ, J., et al., Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival, Br J Haematol, 118 (4), 1034-1040, 2002.
71. MENU, E., ASOSINGH, K., VAN RIET, I., CROUCHER, P., VAN CAMP, B., VANDERKERKEN, K., Myeloma cells (5TMM) and their interactions with the marrow environment, Blood Cells Mol Dis, 33, 111-119, 2004.
72. MICHALOWSKY, L.A., JONES, P.A., Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2’-deoxycytidine resistance, Mol Cell biol, 7 (9), 3076-3083, 1987.
73. MITSIADES, C.S., MITSIADES, N., MUNSHI, N.C., ANDERSON, K.C., Focus on multiple myeloma, Cancer Cell, 6, 439-444, 2004.
74. MITSIADES, C.S., MITSIADES, N.S., MCMULLAN, C.J., POULAKI, V., SHRINGARPURE, R., HIDESHIMA, T., et al., Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications, Proc Natl ACAD USA, 101 (2), 540-545, 2004.
75. MIYAKE, M., NAKANO, K., LEKI, Y., ADACHI, M., HUANG, C.L., ITOI, S., et al., Motility related protein 1 (MRP1/CD9) expression: inverse correlation with metastases in breast cancer, Cancer Res, 55 (18), 4127-4131, 1995.
76. MORI, M., MIMORI, K., SHIRAISHI, T., HARAGUCHI, M., UEO, H., BARNARD, G.F., et al., Motility related protein 1 (MRP1/CD9) expression in colon cancer, Clin Cancer Res, 4 (6), 1507-1510, 1998.
77. MURAI, M., TOYOTA, M., SATOH, A., SUZUKI, H., AKINO, K., MITA, H., SASAKI, Y., ISHIDA, T., SHEN, L., GARCIA-MANERO, G., ISSA, J.P., HINODA, Y., TOKINO, T., IMAI, K., Abberant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours, Br J Cancer, 92 (6), 1165-1172, 2005.
78. NG, M.H., CHUNG, Y.F., LO, K.W., WICKHAM, N.W., LEE, J.C., HUANG, D.P., Frequent hypermethylation of p16 and p15 genes in multiple myeloma, Blood, 87 (7), 2500-2506, 1997.
79. NG, M.H., TO, K.W., LO, K.W., CHAN, S., TASNG, K.S., CHENG, S.H., et al., Frequent death-associated protein kinase promotor hypermethylation in multiple myeloma, Clin Cancer Res, 7 (6), 1724-1729, 2001.
80. NG, M.H., Death associated protein kinase: from regulation of apoptosis to tumor suppressive functions and B cell malignancies, Apoptosis, 7 (3), 261-270, 2002.
81. PEI, X.Y., DAI, Y., GRANT, S., Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors, Clin Cancer Res, 10 (11), 3839-3852, 2004.
82. PODAR, K., ANDERSON, K.C., The pathophysiological role of VEGF in hematological malignancies: therapeutic implications, Blood, 105, 1383-1395, 2005.
83. POMPEIA, C., HODGE, D.R., PLASS, C, WU, Y.Z., MARQUEZ, V.E., KELLEY, J.A., et al., Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line, Cancer Res, 64 (10), 3465-3473, 2004.
84. RADL, J., Multiple myeloma and related disorders. Lessons from an animal model, Pathol. Biol., 47, 109-114, 1999.
85. RICHARDS, E.J., ELGIN, S.C., Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects, Cell, 108, 489-500, 2002.
86. RISAU, W., Mechanisms of angiogenesis, Nature, 386, 671-674, 1997.
87. ROITT, I., BROSTOFF, J., MALE, D., Immunology, Mosby, zesde editie, 2001.
88. RUBINSTEIN, E., BENOIT, P., BILLARD, M., PLAISANCE, S., PRENANT, M., UZAN, G., et al., Organization of the human CD9 gene, Genomics, 16 (1), 132-138, 1993.
89. SAHOTA, S.S., GARAND, R., MAHROOF, R., SMITH, A., JUGE-MORINEAU, N., STEVENSON, F.K., BATAILLE R., VH gene analysis of IgM-secreting Myeloma indicates an origin from a memory cell undergoing isotype switch events, Blood, 94, 1070-1076, 1999.
90. SANTI, D.V., NORMENT, A., GARRETT, C.E., Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine, Proc Natl Acad Sci USA, 81 (22), 6993-6997, 1984.
91. SANTINI, V., KANTARJIAN, H.M., ISSA , J.P., Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications, Ann Intern Med, 134 (7), 573-586, 2001.
92. SAUER, G., WINDISCH, J., KURZEDER, C;, HEIMANN, V., KREIENBERG, R., DEISSLER, H., Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion, Clin Cancer Res, 9 (17), 6426-6431, 2003.
93. SERRU, V., et al., Sequence and expression of seven new tetraspans, Biochim Biophys Acta, 1478, 159-163, 2000.
94. SHALLAL, S., KORNBLUTH, J., CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis, Blood, 96 (1), 224-233, 2000.
95. SI, Z. HERSEY, P., Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma, Int J Cancer, 54 (1), 37-43, 1993.
96. SINGAL, R., GINDER, G.D., DNA methylation, Blood, 93 (12), 4059-4070, 1999.
97. TASAKA, T., ASOU, H., MUNKER, R., SAID, J.W., BERENSON, J., VESCIO, E., HERNANDEZ, J., et al., Methylation of the p16INK4A gene in multiple myeloma, Br J Haematol, 101 (3), 558-564, 1998.
98. VACCA, A., RIBATTI, D., RONCALI, L., RANIERI, G., SERIO, G., SILVESTRIS, F., DAMMACCO, F., Bone marrow angiogenesis and progression in Multiple myeloma, British Journal Haematology, 87, 503-508, 1994.
99. VANDERKERKEN, K., DE GREEF C., ASOSINGH, K., ARTETA, B., DE VEERMAN, M., VANDE BROECK, I., VAN RIET, I., KOBAYASHI, M., SMEDSROD, B., VAN CAMP, B., Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KaLwRij mouse, British Journal of Cancer, 82, 953-959, 2000.
100. VANDERKERKEN, K., ASOSINGH, K., CROUCHER, B., VAN CAMP, B., Multiple myeloma biology: lessons from the 5TMM models, Immunol Rev, 194, 196-206, 2003.
101. VAN SOEST, S., et al., Retinitis pigmentosa: defined from a molecular point of view, Surv Ophthalmol, 43, 321-334, 1999.
102. VAN VALCKENBORG, E., DE RAEVE, H., DEVY, L., BLANCHER, S., MUNAUT, C., NOEL, A., VAN MARCK, E., VAN RIET, I., VAN CAMP, B., VANDERKERKEN, K., Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo, British Journal of Cancer, 86, 796-802, 2002.
103. VIGNA, E., NALDINI, L., Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy, The Journal of Gene Medicine, 2, 308-316, 2000.
104. VILLAR-GAREA, A., ESTELLER, M., Histone deacetylase inhibitors: understanding a new wave of anticancer agents, Int. J., Cancer, 112, 171-178, 2004.
105. WRIGHT, M.D., MOSELEY, G.W., VAN SPRIEL, A.B., Tetraspanin microdomains in immune cell signaling and malignant disease, Tissue Antigens, 64, 533-542, 2004.
106. YASUI, H., HIDESHIMA, T., RICHARDSON, P.G., ANDERSON, K.C., Novel therapeutic strategies targetting growth factor signalling cascades in multiple myeloma, Br J Haematol, 132 (4), 285-397, 2006.
107. YOSHIDA, M., KIJIMA, M., AKITA, M., BEPPU, T., Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A, J Biol Chem, 265, 17174-17179, 1990.
108. ZHONG, S., FIELDS, C.R., Su, N., PAN, Y.X., ROBERTSON, K.D., Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of abberant DNA methylation and histone deacetylation in lung cancer, Oncogene, 26 (18), 2621-2634, 2007.
109. ZHOU, Q., ATADJA, P., DAVIDSON, N., Histone Deacetylase Inhibitor LBH589 Reactivates Silenced Estrogen Receptor Alpha (ER) Gene Expression without Loss of DNA Hypermethylation, Cancer Biol Ther, 6 (1), internetpublicatie in 2007.
110. Website van het “Myeloma Institute for Research and Therapy”, http://myeloma.uams.edu.
111. Website van het “Multiple Myeloma Research Foundation” (MMRF), http://www.multiplemyeloma.org.
112. Website van het “International Myeloma Foundation”, http://www.myeloma.org.
113. Website van het “National Cancer Institute”, http://www.cancer.gov, http://www.cancer.gov/cancerinfo/wyntk/myeloma.
114. http:cook.chem.ndsu.nodak.edu/mmp.shtml
115. Website van het “College of natural sciences and mathematics departement of Biological Science, Cal state Fullerton, Californië, Verenigde Staten, http://biology.fullerton.edu.
116. Website van de “Ecole polythechnique fédérale de Lausanne, School of life sciences, Zwitserland, http://sv.epfl.ch/IntraLEN/anglais/viral.html.